RxDoctor Payments DataLook up a doctor →

Richard Heck, MD

Family Medicine · North Little Rock, ARNPI 1295833739

Payments from drug & device makers

$12,504in general payments, 2019–2025

Across 841 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • AstraZeneca$988
  • Lilly USA, LLC$979
  • GSK$928
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$12,471100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,504 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$154,072
Medicare patients
597
Services billed
5,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide176$186,258
MounjaroTirzepatide80$97,037
JardianceEmpagliflozin84$88,590
EliquisApixaban105$85,452
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$58,227
FarxigaDapagliflozin Propanediol60$58,010
XareltoRivaroxaban21$26,438
LinzessLinaclotide25$23,815
Breo ElliptaFluticasone/Vilanterol46$23,394
Repatha SureclickEvolocumab20$13,415
Tresiba Flextouch U-100Insulin Degludec18$9,351
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,629
Tresiba Flextouch U-200Insulin Degludec12$7,272
Atorvastatin Calcium768$6,519
MyrbetriqMirabegron11$4,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,349$186,258176 claims
Lilly USA, LLCMounjaro$979$97,03780 claims
Boehringer IngelheimJardiance$791$88,59084 claims
PfizerEliquis$796$85,452105 claims
GSKTrelegy Ellipta, Breo Ellipta$928$81,621123 claims
AstraZenecaFarxiga$988$58,01060 claims
Johnson & JohnsonXarelto$205$26,43821 claims
AbbVieLinzess$1,550$23,81525 claims
Astellas Pharma US IncMyrbetriq$459$4,76211 claims
Kowa Pharmaceuticals America, Inc.Livalo$64$1,86912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →